Search results for "Review"

showing 10 items of 4492 documents

Development and description of New Nordic Diet scores across infancy and childhood in the Norwegian Mother, Father and Child Cohort Study (MoBa)

2021

Abstract In recent years, examining dietary patterns has become a more common way of investigating potential associations between diet and adverse health outcomes. The New Nordic Diet (NND) is a potentially healthy and sustainable dietary pattern characterized by foods that are locally available and traditionally consumed in the Nordic countries. The diet has been typically examined in adult populations, and less is known about compliance to the NND from infancy throughout childhood. In the current study, we therefore aimed to develop and describe child age‐specific NND scores. This study is based on the Norwegian Mother, Father and Child Cohort Study (MoBa) and uses data from the Medical B…

0301 basic medicineNew Nordic DietMaleChild agePediatricsCohort StudiesFathers0302 clinical medicinePregnancy030212 general & internal medicineNutritional diseases. Deficiency diseasesMoBachildNutrition and DieteticsNorwayObstetrics and GynecologyCognitionDietary patternPeer reviewVDP::Medisinske Fag: 700::Helsefag: 800languageOriginal ArticleFemalediet scoresCohort studyMental developmentAdultRC620-627MothersNorwegianRJ1-57003 medical and health sciencesmedicineHumansPregnancy030109 nutrition & dieteticsbusiness.industryPublic Health Environmental and Occupational HealthInfant NewbornInfantGynecology and obstetricsOriginal Articlesmedicine.diseaseMBRNlanguage.human_languageDietPediatrics Perinatology and Child HealthRG1-991businessDemographyMaternal & Child Nutrition
researchProduct

Sucralose and Cardiometabolic Health: Current Understanding from Receptors to Clinical Investigations

2021

International audience; The excess consumption of added sugar is consistently found to be associated with weight gain, and a higher risk of type 2 diabetes mellitus, coronary heart disease, and stroke. In an effort to reduce the risk of cardiometabolic disease, sugar is frequently replaced by low- and null-calorie sweeteners (LCSs). Alarmingly, though, emerging evidence indicates that the consumption of LCSs is associated with an increase in cardiovascular mortality risk that is amplified in those who are overweight or obese. Sucralose, a null-caloric high-intensity sweetener, is the most commonly used LCS worldwide, which is regularly consumed by healthy individuals and patients with metab…

0301 basic medicineNon-Nutritive SweetenersSucroseSucraloseCalorieglucose metabolismMedicine (miscellaneous)030209 endocrinology & metabolismReviewOverweightGut floraAdded sugar03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEnvironmental healthmedicineHumansGlucose homeostasis2. Zero hungerNutrition and Dieteticsbiologybusiness.industrysweet and bitter taste receptorType 2 Diabetes Mellitussucralosetaste signaling cascadecardiovascular healthbiology.organism_classification3. Good health030104 developmental biologyDiabetes Mellitus Type 2chemistryCardiovascular Diseaseslow-calorie sweetenermedicine.symptombusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionWeight gainFood ScienceAdvances in Nutrition
researchProduct

Nut and legume consumption and human health: an umbrella review of observational studies

2021

Consumption of nuts and legumes has been associated with several health benefits. The aim of this study was to systematically review existing meta-analyses of observational studies on nut and legume intake and non-communicable diseases, and assess the level of evidence. Out of the six meta-analyses focussed on legume and 15 on nut intake, a possible association with decreased risk of colorectal adenoma and coronary heart disease was found for higher legume consumption, and a decreased risk of cardiovascular and cancer mortality, colon cancer, hypertension and ischaemic stroke for higher nut consumption. The association between legume consumption and cardiovascular diseases (CVDs), as well a…

0301 basic medicineNut030209 endocrinology & metabolismColorectal adenomameta-analysiBrain Ischemia03 medical and health sciences0302 clinical medicineMeta-Analysis as TopicRisk Factorscardiovascular diseaseNeoplasmsEnvironmental healthVegetablesmedicineHumansNutscancercoronary heart diseaseumbrella review.NutConsumption (economics)030109 nutrition & dieteticsumbrella reviewbusiness.industryIncidence (epidemiology)Confoundingdigestive oral and skin physiologyCancerfood and beveragesFabaceaelegumemedicine.diseaseDietStrokemeta-analysisObservational Studies as TopicCardiovascular DiseasesMeta-analysisHypertensionObservational studycoronary heart diseasesbusinessFood Science
researchProduct

Stimulus Driven Functional Transformations in the Early Olfactory System.

2021

Olfactory stimuli are encountered across a wide range of odor concentrations in natural environments. Defining the neural computations that support concentration invariant odor perception, odor discrimination, and odor-background segmentation across a wide range of stimulus intensities remains an open question in the field. In principle, adaptation could allow the olfactory system to adjust sensory representations to the current stimulus conditions, a well-known process in other sensory systems. However, surprisingly little is known about how adaptation changes olfactory representations and affects perception. Here we review the current understanding of how adaptation impacts processing in …

0301 basic medicineOlfactory systemmedia_common.quotation_subjectNeurosciences. Biological psychiatry. NeuropsychiatrySensory systemOlfactionReviewadaptationBiologyStimulus (physiology)03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicinePerceptionmedicinemedia_commonOlfactory receptormitral and tufted cellsOlfactory bulb030104 developmental biologymedicine.anatomical_structureOdorCellular Neuroscienceolfactory bulbolfactory receptor neuronsNeuroscience030217 neurology & neurosurgerypsychological phenomena and processesRC321-571olfactionFrontiers in cellular neuroscience
researchProduct

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.

2020

The treatment of metastatic non-small cell lung cancer (NSCLC) has undergone a paradigm shift over the last decade. Better molecular characterization of the disease has led to the rapid improvement of personalized medicine and the prompt delivery of targeted therapies to patients with NSCLC. The discovery of the EML4-ALK fusion gene in a limited subset of patients affected by NSCLC and the subsequent clinical development of crizotinib in 2011 has been an impressive milestone in lung cancer research. Unfortunately, acquired resistances regularly develop, hence disease progression occurs. Afterward, modern tyrosine kinase inhibitors (TKIs), such as ceritinib, alectinib, brigatinib, and lorlat…

0301 basic medicineOncologyAlectinibALK inhibitorsmedicine.medical_specialtybrigatinibBrigatinibmedicine.medical_treatmentPharmaceutical Sciencenon-small cell lung cancer (NSCLC)lcsh:Medicinelcsh:RS1-441ReviewALK inhibitorTargeted therapylcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinelorlatinibInternal medicineDrug DiscoveryMedicineAnaplastic lymphoma kinaseceritinibalectinibensartinibcrizotinibCrizotinibCeritinibbusiness.industrylcsh:Rmedicine.diseaseLorlatinibrespiratory tract diseasesnon-small cell lung cancer (NSCLC)030104 developmental biologytyrosine kinase inhibitors (TKIs)030220 oncology & carcinogenesisMolecular Medicinebusinessmedicine.drugPharmaceuticals (Basel, Switzerland)
researchProduct

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib

2017

Abstract: Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments. The only approved second-line therapies for patients without targetable oncogenic drivers are docetaxel, gemcitabine, pemetrexed, and erlotinib and for patients with target-specific oncogenes afatinib, osimertinib, crizotinib, alectinib, and ceritinib. In recent years, evidence on the role of antiangiogenic agents have been established as important and effective therapeutic targets in non-small cell lung cancer (NSCLC). Nintedanib is a tyrosine kinas…

0301 basic medicineOncologyAlectinibmedicine.medical_specialtyAfatinibReview03 medical and health scienceschemistry.chemical_compoundangiogenesis0302 clinical medicineInternal medicinemedicinenintedanibOsimertinibnon-small cell lung cancerclinical trialsCeritinibCrizotinibbusiness.industrytarget therapyangiogenesiclinical trialGeneral Medicinerespiratory tract diseases030104 developmental biologyDocetaxelchemistry030220 oncology & carcinogenesissecond-line treatmentMedicineangiogenesis; clinical trials; nintedanib; non-small cell lung cancer; second-line treatment; target therapyNintedanibErlotinibHuman medicinebusinessmedicine.drug
researchProduct

The Current Landscape of Clinical Trials for Systemic Treatment of HCC

2021

Simple Summary Liver cancer is a life-threatening disease. Apart from surgery and catheter-guided therapies, drugs are a central pillar for its treatment. Clinical trials are research studies that are designed to evaluate the treatment effect of a given drug. Therefore, they are the driving force behind innovation and medical progress. One such innovation in the past years has been immunotherapy, which has become increasingly important for treating cancer. Recently, the first such therapy has been approved for the treatment of liver cancer. Current clinical trials are exploring the benefit of immunotherapy and other therapies for this disease. This article gives an overview of such trials p…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyCombination therapyBevacizumabPembrolizumabReviewdrugscombination therapyliver cancer03 medical and health sciences0302 clinical medicineAtezolizumabInternal medicinemedicineneoplasmsRC254-282therapybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmune checkpointdigestive system diseasesReview articleClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisimmunotherapyNivolumabbusinessmedicine.drugCancers
researchProduct

Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine.

2020

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) causes massive medical problems because of late diagnosis and limited responsiveness to standard chemotherapeutic treatments. This makes PDAC one of the major causes of death by cancer. To address this problem, novel tools for early diagnosis and therapy are needed. The recent development of PDAC organoids, which represent micro-scale mini-tumors, offers promising new options for personalized drug-testing based on primary PDAC patient material. This overview article summarizes and discusses the current state-of-the-art in exploiting the organoid technology to improve clinical management of PDAC. Abstract Pancreatic ductal adenocarcinoma…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPancreatic ductal adenocarcinomaendocrine system diseasesFOLFIRINOXdrug responseReviewchemotherapylcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemedicineDrug responseSurvival rateorganoidsCause of death3D cell culturebusiness.industryCancerPDACpersonalized medicinelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseGemcitabinedigestive system diseases030104 developmental biologyOncology030220 oncology & carcinogenesisPersonalized medicinebusinessmedicine.drugCancers
researchProduct

Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to …

2019

This study aims at clarifying the prognostic role of high-grade tumor budding (TB) in pancreatic ductal adenocarcinoma (PDAC) with the first systematic review and meta-analysis on this topic. Furthermore, we analyzed with a systematic review the relationship between TB and a recently suggested TB-associated mechanism: the epithelial to mesenchymal transition (EMT). Analyzing a total of 613 patients, 251 of them (40.9%) with high grade-TB, we found an increased risk of all-cause mortality (RR, 1.46; 95% CI, 1.13-1.88, p = 0.004; HR, 2.65; 95% CI, 1.79-3.91; p < 0.0001) and of recurrence (RR, 1.61; 95% CI, 1.05-2.47, p = 0.03) for PDAC patients with high-grade TB. Moreover, we found that E…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPancreatic ductal adenocarcinomapancreatic cancerHigh grade tumorReviewEMT; budding; buds; epithelial to mesenchymal transition; pancreatic cancerbuddinglcsh:RC254-28203 medical and health sciences0302 clinical medicineTumor buddingPancreatic cancerInternal medicineMedicineClinical significanceEpithelial–mesenchymal transitionbusiness.industryEMTepithelial to mesenchymal transitionbudslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasebud3. Good health030104 developmental biologyIncreased riskOncology030220 oncology & carcinogenesisMeta-analysisbusinessCancers
researchProduct

Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer

2018

The identification of tumor “oncogenic drivers” and the subsequent development of targeted therapy represented a milestone in the treatment of lung cancer over the last years. Tumor genotyping has been incorporated into therapeutic decision making of advanced non-small cell lung cancer (NSCLC) since has become clear that individuals with actionable molecular alterations receiving a matched targeted agent certainly live longer and better. The recent understanding of biological mechanisms underlying cancer immune evasion has allowed the development of a new class of immunomodulatory agents which are able to reactivate host immune-response, offering the potential for long-term disease control …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtycombinationsoncogene driversmedicine.medical_treatmentnon-small cell lung cancer (NSCLC)Treatment of lung cancerReview Articleoncogene driverTargeted therapyTargeted therapy03 medical and health sciencesInternal medicinemedicineRadiology Nuclear Medicine and imagingLung cancercombinationOncogenebusiness.industryCancerImmunotherapymedicine.diseaseClinical trialnon-small cell lung cancer (NSCLC)030104 developmental biologyOncologyimmunotherapybusiness
researchProduct